[go: up one dir, main page]

IS4774A - Pharmaceutical formulations with vitamin D analogs - Google Patents

Pharmaceutical formulations with vitamin D analogs

Info

Publication number
IS4774A
IS4774A IS4774A IS4774A IS4774A IS 4774 A IS4774 A IS 4774A IS 4774 A IS4774 A IS 4774A IS 4774 A IS4774 A IS 4774A IS 4774 A IS4774 A IS 4774A
Authority
IS
Iceland
Prior art keywords
analogs
vitamin
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
IS4774A
Other languages
Icelandic (is)
Inventor
Hoffmann Karin
Riedl Jutta
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of IS4774A publication Critical patent/IS4774A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IS4774A 1995-12-21 1998-06-15 Pharmaceutical formulations with vitamin D analogs IS4774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19549243A DE19549243A1 (en) 1995-12-21 1995-12-21 Pharmaceutical preparations containing clathrates of cyclodextrins and unnatural vitamin D analogues
PCT/EP1996/005856 WO1997023242A1 (en) 1995-12-21 1996-12-20 Pharmaceutical compositions with vitamin d analogues

Publications (1)

Publication Number Publication Date
IS4774A true IS4774A (en) 1998-06-15

Family

ID=7781710

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4774A IS4774A (en) 1995-12-21 1998-06-15 Pharmaceutical formulations with vitamin D analogs

Country Status (12)

Country Link
EP (1) EP0869819A1 (en)
JP (1) JP2000502733A (en)
KR (1) KR19990076637A (en)
CN (1) CN1207687A (en)
AU (1) AU1306997A (en)
CA (1) CA2241205A1 (en)
DE (1) DE19549243A1 (en)
HU (1) HUP9903935A3 (en)
IL (1) IL125020A0 (en)
IS (1) IS4774A (en)
NO (1) NO982874L (en)
WO (1) WO1997023242A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
DE102005017775A1 (en) * 2005-04-13 2006-10-19 Schering Ag New complex of vitamin-D-compounds with 5Z,7E,10(19)-triene system and methylene derivatives of beta-cyclodextrin, useful for the preparation of medicament and to treat psoriasis
SI1993559T1 (en) 2006-02-03 2017-01-31 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PT2679228T (en) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
KR100822133B1 (en) * 2006-11-06 2008-04-15 한미약품 주식회사 Complex for preventing or treating osteoporosis, comprising solid dispersion of vitamin D or derivatives thereof and bisphosphonates
KR101959952B1 (en) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 Oral controlled release compositions comprising vitamin d compound and waxy carrier
CN104257667B (en) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 Treat vitamin d insufficiency and shortage, secondary hyperparathyroidism and vitamin D-responsive diseases method and composition
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CN106853250A (en) 2008-04-02 2017-06-16 赛特克罗公司 Method, composition, purposes and kit for vitamin D deficiency and associated disorders
ES2783980T3 (en) 2010-03-29 2020-09-21 Opko Ireland Global Holdings Ltd Methods and compositions for the reduction of parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177586B (en) * 1978-12-19 1981-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing stable inclusion complexes of vitamine d with cyclodextrin
JPS5910562A (en) * 1982-07-07 1984-01-20 Teijin Ltd Preparation of pre-1alpha-hydroxycholecalciferol compound
JPS5936656A (en) * 1982-08-23 1984-02-28 Teijin Ltd Novel clathrate compound and drug containing said compound as active component
JPS60120812A (en) * 1983-12-02 1985-06-28 Teijin Ltd Remedy for diabetic osteopenia
DK0437225T3 (en) * 1990-01-10 1994-06-27 Hoffmann La Roche Topical preparations
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
AU1306997A (en) 1997-07-17
CA2241205A1 (en) 1997-07-03
NO982874L (en) 1998-08-20
DE19549243A1 (en) 1997-06-26
HUP9903935A2 (en) 2000-03-28
IL125020A0 (en) 1999-01-26
HUP9903935A3 (en) 2000-05-29
WO1997023242A1 (en) 1997-07-03
NO982874D0 (en) 1998-06-19
CN1207687A (en) 1999-02-10
JP2000502733A (en) 2000-03-07
EP0869819A1 (en) 1998-10-14
KR19990076637A (en) 1999-10-15

Similar Documents

Publication Publication Date Title
BR9610153A (en) Pharmaceutical formulations
BR9611626A (en) Pharmaceutical formulations
DK0585252T3 (en) Pharmaceutical formulations
DK481989D0 (en) PHARMACEUTICAL FORMULATIONS
DE69615887D1 (en) Oral pharmaceutical preparation containing olanzapine
NO962606D0 (en) Pharmaceutical composition
NO961136D0 (en) Pharmaceutical formulation basis for nano-suspensions
BR9610396A (en) Pharmaceutical formulation
IS4774A (en) Pharmaceutical formulations with vitamin D analogs
FI950947L (en) Orally administered pharmaceutical formulations
PT808833E (en) VITAMIN D3 ANALOGS
ITMI921123A0 (en) ORAL PHARMACEUTICAL FORMULATIONS CONTAINING ANTHOCYANOSIDS
DE69614407D1 (en) PHARMACEUTICAL COMPOSITIONS
ID16781A (en) PHARMACEUTICAL FORMULATIONS
LV11727A (en) Pharmaceutical composition
TR199501082A2 (en) Pharmaceutical formulations.
ITMI941169A0 (en) PHARMACEUTICAL FORMULATIONS
FI973280A0 (en) Pharmaceutical composition
FI973230L (en) New pharmaceutical formulation
BR9605777A (en) Pharmaceutical composition
DK0876367T3 (en) Trans apovincamic acid ester derivatives as drugs
NO964309D0 (en) Pharmaceutical composition
SE9502453D0 (en) Drug formulations
EP0852143A4 (en) VITAMIN C STABLE PREPARATION
SE9404467D0 (en) Drug formulations